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the preparation of scientific publications, guidelines, lec-
tures, workshops etc. At the present time the Russian pro-
fessionals actively participate in international randomized
clinical trials but the experience of pharmacoeconomic and
outcome research is very limited. So in the nearest future it
is important to organize adequate economic trials to show
the advantages and the disadvantages of existing health-
care interventions. The independence of investigators may
be guaranteed by governmental funding of such trials
though participation of the pharmaceutical industry seems
to be more real in the present economic crisis.
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Previous research into the usefulness of cost-effectiveness
information in managed care has had a narrow scope.
This research has been limited to the level of importance
that managed care directors place on pharmacoeconomic
(PE) data, the types of studies that MCOs prefer to re-
view and the future use of this type of information. 
OBJECTIVES: The purpose of this study was to ascertain
1) the level of importance that PE information has on the
speed of formulary approval, 2) the relationship between
the cost of therapeutic agents and PE information, 3) the
relationship between the time of market entry/number of
competitor products and requirements for PE informa-
tion, and 4) the importance of PE information by thera-
peutic classification. 
METHODS: A telephone survey of 41 randomly selected
pharmacy directors and medical directors was conducted
to elicit their attitudes towards PE information. 
RESULTS: PE information was somewhat/very impor-
tant in influencing the speed of formulary pull-through in
51.2% of respondents. The majority of respondents felt
that PE information was not important when drug acqui-
sition cost was less than $100; however, its importance
increased as acquisition cost increased. Respondents felt
that the time of market entry influenced the level that
they placed on PE information. When there were no sim-
ilar agents on formulary 73.1% felt that PE data was
somewhat/very important, when there were ten similar
agents on formulary 48.8% of respondents felt that PE
information was somewhat not/not important. Respon-
dents indicated that the therapeutic areas of depression,
asthma, rheumatoid arthritis, pain control, and hyperten-
sion were areas where cost-effectiveness analysis would
be most useful. 
CONCLUSIONS: PE information is relevant to managed
care decision-making and it is influenced by the drug ac-
quisition cost, the number of competitor drugs on market
and the therapeutic area under consideration.
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OBJECTIVE: The purpose of the study was to determine
the potential savings to the Portuguese National Health
System if the utilization of generic medications increased.
METHODS: The total sales of the 100 brand names with
the highest sales to the Portuguese National Health Sys-
tem in 1997 were examined to determine which ones had
a generic equivalent on the market. These were then sub-
stituted in four different scenarios where the substitution
levels were 10%, 25%, 50%, and 100% and the total
sales after substitution was calculated for each scenario.
Finally, the potential savings were determined. 
RESULTS: Of the 100 brand names with the highest sales
to the Portuguese National Health System in 1997, 18
had generic equivalents on the market. When these were
substituted at a 10% level, the estimated savings were
833.037.000 PTE (3.2%). When the substitution levels
were 25%, the estimated savings were 2.082.592.000 PTE
(8.0%). When the substitution level was 50%, the esti-
mated savings were 4.165.185.000 PTE (16.0%). When
the substitution level was 100%, the estimated savings
were 8.330.370.000 PTE (32.0%). 
CONCLUSION: Our pharmacoeconomic analysis dem-
onstrated that the Portuguese National Health System
can save a significant amount of its pharmacy budget by
increasing the utilization of generic medications.
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OBJECTIVE: The aim of this study was to study the
present situation regarding perceptions, understanding
and attitude towards pharmacoeconomics in Norway
among employees within the pharmaceutical authorities
and the pharmaceutical industry, prior to the introduc-
tion of pharmacoeconomic guidelines. 
METHODS: Personal interviews of employees working
with medicines on various levels were conducted, 47
from the authorities and 47 from the industry. The inter-
view included questions regarding associations to various
pharmacoeconomic expressions and questions about atti-
tude towards within which areas that pharmacoeconomic
analyses could be of use and the extent to which pharma-
coeconomic analyses should be implemented. The quanti-
tative data was handled in the statistical programme
SPSS. Factor analysis was used to find correlation among
some of the attitude questions. 
